Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Golden Brick Biotechnology Co Ltd
Shandong, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Phase I safety trial for UCB-NK cell therapy in recurrent ovarian cancer patients, with 12 patients included. The therapy involves intraperitoneal infusion of UCB-NK cells generated from CD34+ hematopoietic progenitor cells from allogeneic umbilical cord blood units.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Cell therapy (UCB-NK cell therapy)
- Industry
- Biotech
Beyond the preview
Go deeper on Shandong Golden Brick Biotechnology Co Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shandong Golden Brick Biotechnology Co Ltd.